Delta-Fly Pharma, Inc. Price (4598.T)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

7,190,965

(26.9084)%

Delta-Fly Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclin... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $445-903
  • Market Cap 5.75B
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Mr. Kiyoshi Eshima Ph.D.
  • IPO Date: October, 12, 2018
  • Country: JP
  • Currency: JPY
  • Headquaters: No Data
  • Employees: 13

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation